-transparent.png){kind=logo}
A mouse (C57BL/6) monoclonal antibody M2590, which is established against syngeneic melanoma B16 cells, reacted with chemically synthesized GM3. NeuAc alpha 2-3Gal beta 1-4Glc beta 1-1' ceramide (24:0/d 18:1), but not with its stereoisomer, NeuAc beta 2-3Gal beta 1-4Glc beta 1-1' ceramide (24:0/d 18:1).
Related Publications
Y Hirabayashi, and
M Sugimoto, and
T Ogawa, and
M Matsumoto, and
M Tagawa, and
M Taniguchi
October 1985,
The Journal of biological chemistry,
Y Hirabayashi, and
M Sugimoto, and
T Ogawa, and
M Matsumoto, and
M Tagawa, and
M Taniguchi
May 2007,
Biochemical and biophysical research communications,
Y Hirabayashi, and
M Sugimoto, and
T Ogawa, and
M Matsumoto, and
M Tagawa, and
M Taniguchi
June 2000,
Hybridoma,
Y Hirabayashi, and
M Sugimoto, and
T Ogawa, and
M Matsumoto, and
M Tagawa, and
M Taniguchi
December 2008,
Cancer immunology, immunotherapy : CII,
Y Hirabayashi, and
M Sugimoto, and
T Ogawa, and
M Matsumoto, and
M Tagawa, and
M Taniguchi
May 2007,
Clinical cancer research : an official journal of the American Association for Cancer Research,
Y Hirabayashi, and
M Sugimoto, and
T Ogawa, and
M Matsumoto, and
M Tagawa, and
M Taniguchi
January 2011,
ISRN dermatology,
Y Hirabayashi, and
M Sugimoto, and
T Ogawa, and
M Matsumoto, and
M Tagawa, and
M Taniguchi
January 1989,
Progress in clinical and biological research,
Y Hirabayashi, and
M Sugimoto, and
T Ogawa, and
M Matsumoto, and
M Tagawa, and
M Taniguchi
February 2004,
Cancer immunology, immunotherapy : CII,
Y Hirabayashi, and
M Sugimoto, and
T Ogawa, and
M Matsumoto, and
M Tagawa, and
M Taniguchi
August 1997,
Melanoma research,
Y Hirabayashi, and
M Sugimoto, and
T Ogawa, and
M Matsumoto, and
M Tagawa, and
M Taniguchi
November 1990,
Journal of the National Cancer Institute,
